Suppr超能文献

缅甸移民中的乙型肝炎:基因型及其临床相关性。

Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance.

机构信息

Victorian Infectious Diseases Service, at the Doherty Institute, The Royal Melbourne Hospital, Melbourne, Victoria.

Department of Medicine/ RMH, at the Doherty Institute, University of Melbourne, Melbourne, Victoria.

出版信息

J Med Virol. 2018 Feb;90(2):271-276. doi: 10.1002/jmv.24939. Epub 2017 Sep 26.

Abstract

Hepatitis B virus (HBV) from 76 adult immigrants in Australia from Myanmar was characterized to determine the prevalence of different HBV genotypes and subgenotypes. A mutational analysis was then performed to determine the presence of clinically significant mutations and correlate them to clinical outcomes. Initial genotyping revealed 68 patients with genotype C (89.5%) and eight patients with genotype B (10.5%). Phylogenetic analysis revealed the large majority of the genotype C infections were of subgenotype C1 (67/68). Sequencing of the HBV polymerase gene (and overlapping surface gene) revealed no mutations associated with antiviral resistance. HBV surface gene mutations were detected in 10 patients with subgenotype C1. HBV BCP/PC sequencing was obtained for 71/76 (93%) patients. BCP and/or PC mutations were identified in 57/71 (80%) of PCR positive patients. Treatment had been commenced for 15/76 (18%) patients, a further 26 untreated patients were in a stage of disease where HBV treatment would be considered standard of care. It was identified that genotype C1 is the predominant sub-genotype in this population. Genotype C is known to be associated with increased risk of development of HCC. This highlights the need for screening for HCC given the potential for the development of liver cancer. It was also identified that people with HBV were potentially not receiving optimal therapy in a timely fashion.

摘要

对来自澳大利亚缅甸的 76 名成年移民的乙型肝炎病毒 (HBV) 进行了特征描述,以确定不同 HBV 基因型和亚型的流行情况。然后进行了突变分析,以确定是否存在临床意义重大的突变,并将其与临床结果相关联。初步基因分型显示 68 例患者为基因型 C(89.5%),8 例患者为基因型 B(10.5%)。系统进化分析显示,绝大多数基因型 C 感染属于亚基因型 C1(67/68)。HBV 聚合酶基因(和重叠表面基因)的测序未发现与抗病毒耐药性相关的突变。在 10 例 C1 亚基因型患者中检测到 HBV 表面基因突变。对 76/76(93%)名患者进行了 HBV BCP/PC 测序。在 57/71(80%)PCR 阳性患者中发现了 BCP 和/或 PC 突变。15/76(18%)名患者已开始治疗,26 名未治疗的患者处于疾病阶段,HBV 治疗将被视为标准护理。确定该人群中主要的亚基因型是 C1。已知基因型 C 与 HCC 发展风险增加相关。这凸显了鉴于肝癌发展的可能性,对 HCC 进行筛查的必要性。还确定了 HBV 患者可能没有及时接受最佳治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验